GeneDx focuses on clinical genomics and rare disease diagnostics through genetic testing, analyzing DNA to identify mutations linked to health conditions. They have sequenced over 300,000 clinical patient exomes and provide rapid testing services, with results available in as little as seven days. This quick turnaround is essential for timely diagnoses that can improve treatment outcomes. GeneDx aims to lead in the field by offering reliable genetic testing that supports personalized medicine.

Perceptive Advisors

Sema4

Biotechnology

Healthcare

GeneDx

In early 2024, GeneDx announced enhancements to its Whole Genome Sequencing (WGS) product, aimed at accelerating diagnoses for patients with genetic conditions.

The story of GeneDx (WGS) and its 2,434.65% stock surge in 2024

- GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.

GeneDx Launches Tool to Fuel Rare Disease Drug Discovery

What You Should Know:– GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.– The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.Addressing the Challenges of Drug DevelopmentThe traditional drug development process is lengthy, costly, and often unsuccessful. On average, it takes 12 years and $2.6 billion to bring a new drug to market, with a 90% failure rate. GeneDx Discover aims to address these challenges by leveraging the power of genetic data to improve decision-making and accelerate the development timeline.Unlocking the Potential of Genetic DataGeneDx Discover provides biopharmaceutical companies with:Access to a vast dataset: Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes.Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes. Self-service data exploration: Offers an easy-to-use interface for exploring and analyzing genetic data.Offers an easy-to-use interface for exploring and analyzing genetic data. Deeper understanding of patient populations: Provides insights into disease prevalence, phenotypic information, and variant-level details.Provides insights into disease prevalence, phenotypic information, and variant-level details. Enhanced decision-making: Enables data-driven decisions throughout the drug development process.Enables data-driven decisions throughout the drug development process

Genedx Launches Tool To Fuel Rare Disease Drug Discovery

Genedx Launches Ai Tool To Fuel Rare Disease Drug Discovery

GeneDx (WGS) announced the appointment of Heidi Chen as chief legal officer, effective November 25.

GeneDx appoints Heidi Chen as chief legal officer

Calamos Advisors LLC invests $1.14 million in GeneDx Holdings Corp. (NASDAQ:WGS).

Calamos Advisors LLC Invests $1.14 Million in GeneDx Holdings Corp. (NASDAQ:WGS)

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Global Genes' Annual Week In Rare Event Heading To Kansas City

InvestingPro Data reveals a market capitalization of $811.85 million for GeneDx Holdings, reflecting the company's size and investor valuation in the market.

Opko Health offloads $2.98m in GeneDx Holdings stock

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients.“Receiving a genetic diagnosis can be critical in a child’s journey toward effective treatment and care, and we are thrilled our biopharma counterparts recognize the value that exome testing offers to pediatric epilepsy patients over traditional panel testing,” said Katherine Stueland, Chief Executive Officer at GeneDx. “We believe that cost should never be a barrier in accessing critical health information and we are steadfast in our commitment to investing in partnerships that allow us the opportunity to expand access to exome and genome testing for all patients who can benefit.”Through the patient access program, GeneDx is helping to ensure more equitable care across patient populations. While payor coverage for exome testing has improved, this program may help expand access of necessary genetic testing for pediatric epilepsy patients.Exome testing is recommended as a first-line test for individuals with unexplained epilepsy by the National Society of Genetic Counselors and these guidelines are endorsed by the American Epilepsy Society.1 In addition to these medical guidelines, research shows that a genetic diagnosis can further guide clinical decisions, with patients experiencing up to 90% seizure reduction in some cases and up to 80% of cases having implications for treatment and management.2 However, despite the overwhelming clinical support and guidelines, access to testing is sparse, and genetic diagnosis for rare disorders, including epilepsy, can take up to 5 years.3Expanding access to exome testing not only ensures that more patients receive a diagnosis, with exome diagnostic rates for epilepsy at nearly 25% compared to the less than 20% diagnostic rate offered by multi-gene panels,4 but it also creates the opportunity for GeneDx to better understand gene-disease relationships through the robust data and insights delivered with an exome result. The utilization of this program will continue to fuel GeneDx’s industry-leading rare-disease data set, which can help support biopharma partners to bring therapies to patients faster, by accelerating clinical trial recruitment and drug discovery.To be eligible for the Patient Access Program: Epilepsy patients must meet certain criteria, including the following:Patient must reside in the United StatesPatient’s ordering provider must be authorized under applicable law to order genetic testing in the United StatesPatient must have experienced their first unprovoked seizure under 8 years of agePatient must not have had prior genetic testing performed by a clinical laboratory which confirmed a diagnosis of a neurodevelopmental disorder (NDD)Patient must be less than 18 years of ageThe new patient access program is rolling out to select ordering providers today, with a complete availability in July. To learn more, visit genedx.com/epilepsy.About GeneDx :GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care

Genedx Announces Patient Access Program To Expand Access To Exome Testing For Pediatric Epilepsy Patients

GeneDx Holdings Corp.The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicineSTAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.“The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx. "We continue to see increased investment in rare disease drug discovery and want to help accelerate access to these life changing treatments by making our data more easily accessible to the companies on the forefront of these discoveries.”GeneDx's rare disease data set is recognized for its depth and accuracy, making it a valuable resource for biopharmaceutical companies seeking to identify novel therapeutic targets and optimize clinical trial design. As a MapEnhance specialty partner, GeneDx’s rich repository of de-identified genetic data will be accessible through Komodo’s end-to-end platform, to help companies unlock deeper insights into genetically based disease and accelerate new breakthroughs and treatments for patients."Combining the power of GeneDx’s genetic intelligence with Komodo’s comprehensive and longitudinal view into patient journeys is going to be a massive accelerant for companies looking to advance precision medicine and help to pave the way for more personalized treatments for patients,” said Brad Kelley, General Manager of MapEnhance, Komodo Health. “We are thrilled to welcome GeneDx to the MapEnhance family and help our customers more quickly unravel the intricate genetic underpinnings of diseases."GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th. At the meeting, GeneDx will present a panel “Enabling precision medicine as the standard of care,” looking at different perspectives of the lab, biopharma and a parent perspective, on how genomic information can advance precision medicine

Genedx Announces Partnership With Komodo Health To Expand Access To World'S Largest Rare Disease Dataset

Genetic testing for rare disease diagnostics

GeneDx

Genetic testing for rare disease diagnostics

GeneDx

Genetic testing for rare disease diagnostics

About

Simplify's Take

What believers are saying

What critics are saying

What makes GeneDx unique

Benefits

Recently Posted Jobs

GeneDx is Hiring for 0 Jobs on Simplify!